Segments (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended			9 Months Ended
	Sep. 30, 2014		Sep. 30, 2013	Sep. 30, 2014		Sep. 30, 2013	Dec. 31, 2013
Segment Reporting Information [Line Items]
Product revenues	$ 17,291		$ 16,563	$ 58,510		$ 50,708
Revenue from services	2,482		2,770	6,606		9,050
Revenue from transfer of intellectual property	0		1,308	476		16,080
Operating (loss) income	(48,201)		(19,010)	(113,361)		(43,766)
Depreciation and amortization	3,678		3,768	11,269		10,648
Total revenues	19,773		20,641	65,592		75,838
Assets	1,295,242	[1]		1,295,242	[1]		1,391,516	[1]
Goodwill	224,769	[1]		224,769	[1]		226,373	[1]
United States [Member]
Segment Reporting Information [Line Items]
Total revenues	2,482		4,078	7,082		25,130
Chile [Member]
Segment Reporting Information [Line Items]
Total revenues	7,622		7,993	22,758		24,216
Spain [Member]
Segment Reporting Information [Line Items]
Total revenues	4,414		4,026	16,230		13,503
Israel [Member]
Segment Reporting Information [Line Items]
Total revenues	3,710		3,099	14,563		9,666
Mexico [Member]
Segment Reporting Information [Line Items]
Total revenues	1,528		1,445	4,905		3,323
Uruguay [Member]
Segment Reporting Information [Line Items]
Total revenues	17		0	54		0
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Product revenues
Revenue from services	60		60	180		180
Revenue from transfer of intellectual property	0		0	0		0
Operating (loss) income	(6,384)		(6,606)	(19,557)		(17,393)
Depreciation and amortization	24		31	72		121
Assets	125,026			125,026			209,539
Goodwill	0			0			0
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Operating (loss) income	(599)		(879)	(1,762)		(2,419)
Pharmaceutical | Operating Segments [Member]
Segment Reporting Information [Line Items]
Product revenues	17,291		16,563	58,510		50,708
Revenue from services	0		0	0		0
Revenue from transfer of intellectual property	0		913	285		14,720
Operating (loss) income	(34,480)		(11,126)	(71,421)		(7,171)
Depreciation and amortization	1,925		2,020	6,061		5,417
Assets	1,061,168			1,061,168			1,065,033
Goodwill	173,804			173,804			175,408
Diagnostics | Operating Segments [Member]
Segment Reporting Information [Line Items]
Product revenues
Revenue from services	2,422		2,710	6,426		8,870
Revenue from transfer of intellectual property	0		395	191		1,360
Operating (loss) income	(6,738)		(399)	(20,621)		(16,783)
Depreciation and amortization	1,729		1,717	5,136		5,110
Assets	109,048			109,048			116,944
Goodwill	$ 50,965			$ 50,965			$ 50,965

[1] As of September 30, 2014 and December 31, 2013, total assets include $7.4 million and $6.7 million, respectively, and total liabilities include $13.1 million and $10.4 million, respectively, related to SciVac Ltd (“SciVac”), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.